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Abstract
Familiar colorectal cancer type X (FCCTX) comprises families that fulfill the Amsterdam criteria for hereditary non-polyposis
colorectal cancer, but that lack the mismatch repair deficiency that defines the Lynch syndrome. Thus, the genetic cause
that increases the predisposition to colorectal and other related cancers in families with FCCTX remains to be elucidated.
Using whole-exome sequencing, we have identified a truncating mutation in the SETD6 gene (c.791_792insA,
p.Met264IlefsTer3) in all the affected members of a FCCTX family. SETD6 is a mono-methyltransferase previously shown to
modulate the NF-jB and Wnt signaling pathways, among other. In the present study, we characterized the truncated ver-
sion of SETD6, providing evidence that this SETD6 mutation may play a role in the cancer inheritance in this family. Here
we demonstrate that the truncated SETD6 lacks its enzymatic activity as a methyltransferase, while maintaining other
properties such as its expression, localization and substrate-binding ability. In addition, we show that the mutant allele is
expressed and that the resulting protein competes with the wild type for their substrates, pointing to a dominant negative
nature. These findings suggest that the identified mutation impairs the normal function of SETD6, which may result in the
deregulation of the different pathways in which it is involved, contributing to the increased susceptibility to cancer in this
FCCTX family.
Introduction
Colorectal cancer (CRC) is the third most common cancer and
the second leading cancer-related cause of death in the world
(1,2). It is estimated that familial risk is involved in up to 30% of
all CRC cases (3,4), although not more than 5–6% are caused by
known germline mutations in cancer-predisposing genes (5).
Hereditary non-polyposis colorectal cancer (HNPCC) is the most
common form of inherited CRC. HNPCC is a familial syndrome
characterized by an increased incidence of CRC and other
extracolonic tumors (6) that has been defined by the
Amsterdam I and II clinical criteria (7,8). Approximately half of
HNPCC families are referred to as Lynch syndrome, since they
are explained by germline inactivating mutations in the mis-
match repair (MMR) genes—including MLH1, MSH2, MSH6 and
PMS2—or by a large deletion in EPCAM (located upstream of
MSH2) (9,10). As a consequence, Lynch syndrome tumors lack
the corresponding MMR proteins and fail to repair DNA through
the mismatch repair pathway. This, in turn, causes microsatel-
lite instability (MSI) and leads to the accumulation of somatic
mutations. It is worth noting that although HNPCC and Lynch
Syndrome used to be employed as synonyms, nowadays HNPCC
is defined by the clinical criteria (Amsterdam I or II), while
Lynch Syndrome refers to the families with MMR defects.
Received: August 6, 2017. Revised: August 6, 2017. Accepted: August 15, 2017
VC The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
4481
Human Molecular Genetics, 2017, Vol. 26, No. 22 4481–4493
doi: 10.1093/hmg/ddx336









niversity of Liege user on 26 M
ay 2021
The other half of HNPCC families are MMR-proficient and
present microsatellite-stable (MSS) tumors. These cases have
been grouped under the term familial colorectal cancer type X
(FCCTX), and the genetic basis underlying their cancer predispo-
sition remains unknown (11). Several studies have reported that
the tumors from FCCTX patients have different molecular and
clinical features than both Lynch syndrome and sporadic CRC
(12,13), suggesting the presence of other forms of genomic insta-
bility. FCCTX’s tumors also show distinct gene expression pro-
files and deregulation of different canonical pathways, although
some similarities have been described between FCCTX and MSS
sporadic tumors (12,14,15). These alterations could result in the
deregulation of genes involved in chromosomal segregation, ge-
nomic instability, apoptosis, proliferation, growth inhibition
and migration (14,16). Nonetheless, FCCTX is a heterogeneous
group of families, and we are still far from fully understanding
the different events that may be involved in their tumor pro-
gression. In the same way, our knowledge regarding the genetic
alterations that contribute to FCCTX’s heredity is fairly limited.
Although previous studies had identified a few genes involved
in the cancer susceptibility of these FCCTX families (17–19), it
was not until the arrival of Next-Generation Sequencing (NGS)
that a larger amount of new cancer-predisposing genes are be-
ing discovered (20). In view of the published results, it seems
that FCCTX does not form a single entity, since multiple differ-
ent genes are thought to be involved in their cancer heritability
(21). However, together they still explain the inheritance in only
a small portion of these FCCTX families. Thus, the identification
of new high-risk genes that contribute to the increased cancer
susceptibility of FCCTX families remains to be a challenge and a
priority.
Covalent post-translational modification (PTM) of proteins is
key for the regulation of many biological processes (22). Among
these modifications, lysine methylation plays a vital role in the
regulation of many cellular signaling pathways (23,24). A lysine
residue in a given protein can accept up to three methyl groups,
forming mono-, di- and tri-methylated derivatives. The most
studied is the methylation of histones, which can either sup-
press or activate gene transcription depending on which lysine
is methylated (25). Similar to histones, non-histone proteins
can be also targeted for methylation with diverse biological out-
comes, such as changes in gene expression, protein stability
and subcellular localization (26–34). Lysine methylation is cata-
lyzed by protein lysine methyltransferases (PKMTs) that trans-
fer a methyl group from a donor S-adenosyl-L-methionine
(SAM) (35–39). Even though there are more than 70 PKMTs pre-
sent in the human proteome, little is known about their enzy-
matic activity beyond histones.
SETD6 (SET domain-containing protein 6) is a member of the
lysine methyltransferase family known to monomethylate
RelA—a subunit of the transcription factor NF-jB—on lysine 310
(RelAK310me1). This methyl mark is recognized by GLP (a his-
tone methyltransferase), which in turn methylates histone H3
on lysine 9, promoting a repressed chromatin state and thereby
silencing the transcription of NF-jB target genes (40). In con-
trast, it was recently reported that SETD6 promotes RelA’s tran-
scriptional activity in bladder cancer (41). Additionally, SETD6
has been proven to participate in the canonical Wnt signaling
cascade by forming a complex with PAK4 (p21-activated kinase
4) and the transcription factor b-catenin at the chromatin, lead-
ing to the activation of b-catenin target gene transcription (42).
In recent studies, SETD6 has also been linked to the regulation
of the nuclear hormone receptor signaling (43), embryonic stem
cell differentiation (44) and oxidative stress response (45,46).
In the present study, we sequenced the whole exome from a
FCCTX family with the aim of identifying new causative cancer-
predisposing genetic variants. Among the different mutations
that were detected, a rare frameshift mutation in the SETD6
gene (resulting in a premature termination of the enzyme) was
identified and further characterized, both in cell-free systems
and in colon cancer cell line models. This mutation causes the
loss of the C-terminal portion of SETD6, leaving an intact cata-
lytic SET domain. Here we demonstrate that, while the trun-
cated protein shows the same subcellular localization and
substrate-binding properties as the wild type, it completely
loses its catalytic activity. We also show that mutant SETD6 is
expressed in the tumor and competes against the wild type in
the ability to methylate its substrate, suggesting a dominant
negative effect. Taken together, our findings support a model by
which a dominant negative mutation in SETD6 may contribute
to FCCTX’s pathology.
Results
Whole-exome sequencing results from FCCTX family
cc598
The whole exome was sequenced from two affected members
and one healthy relative of a FCCTX family (II: 1, II: 2 and II: 3,
Fig. 1A). The corresponding family—known as family cc598—
fulfilled the Amsterdam I criteria (7,8), with four colorectal can-
cers affecting two successive generations and the earliest age at
diagnosis being 34 years old. Supplementary Material, Table S1
shows in detail the clinical data from the different members of
this family.
After rigorous filtering of the variants detected aiming to select
shared rare heterozygote damaging variants, a number of candi-
date genes were prioritized. The candidate variants selected were:
SETD6 c.791_792insA (p.Met264IlefsTer3), CCDC60 c.1558 C>T
(p.Arg20*), L3MBTL1 c.1125 A>G (p.Lys375¼), CCDC62 c.79 C>T
(p.Arg27Trp) and WDR33 c.3266 G>C (p.Arg1089Pro). All the candi-
date variants (detailed in Supplementary Material, Table S2) were
present in the two affected members (II: 1 and II: 2) and absent in
the healthy sibling (II: 3). However, among these, the most relevant
changes in the protein were observed in SETD6.
Rare SETD6 variant cosegregates with CRC within family
cc598
The SETD6 variant was a frameshift mutation known as
c.791_792insA, p.Met264IlefsTer3, or just M264Ifs*3 (rs768456822,
ENST00000310682), and it affected the three main protein-coding
transcripts of this gene (ENST00000310682.6, ENST00000219315.8
and ENST00000394266.8). This mutation consisted of an insertion
of an adenine between positions 791 and 792 of the cDNA and,
like the other candidate variants, was carried by the two affected
members sequenced (II: 1 and II: 2, with CRC diagnosed at ages 64
and 56, respectively), while not present in the healthy sibling (II:
3, 76 years old) (Fig. 1). In addition, the segregation study con-
firmed that the mutation was also present in II: 4 (CRC diagnosed
at 34), while absent in two other healthy relatives (III: 1 and III: 2,
51 and 49 years old, respectively) (Fig. 1 and Supplementary
Material, Fig. S2). The segregation for the other candidate variants
is shown in Supplementary Material, Table S3. Loss of heterozy-
gosity (LOH) analysis of SETD6 c.791_792insA revealed that LOH
did not occur in the tumor of II: 2 (Supplementary Material,
Fig. S2B).












Figure 1. SETD6 mutation c.791_792insA (p.M264Ifs*3) cosegregates with colorectal cancer in a FCCTX family. (A) Pedigree of family cc598 carrying the SETD6 deleterious
mutation c.791_792insA (p.Met264IlefsTer3). Whole-exome sequencing was done in family members II: 1, II: 2 and II: 3, and segregation was studied in members II: 4,
III: 1 and III: 2. All affected participants were carriers (Mutþ), while the healthy were non-carriers (Mut -). Colorectal cancer (CRC)-affected members are marked in
black. The age at diagnosis (dx) or current age of healthy members is included beneath each individual (in years). (B) Electropherogram of the reverse wild-type and
mutant sequence of the SETD6 gene. The arrows show the point where the adenine is inserted.
A B
C D
Figure 2. SETD6 mutation causes the loss of the C-terminal half of the protein, but the mutant protein is still successfully overexpressed. (A) Amino acid sequence of
SETD6 wt and SETD6-N with the changes marked in bold. (B) Representation of the different domains within the SETD6 protein showing the loss produced by the trun-
cation (top), and the effect that the mutation is predicted to have on the 3D structure by SWISS-MODEL (53) (bottom). (C, D) Overexpression of FLAG-SETD6 (wt, N or C)
in HEK293T (C) or HCT116 (D) cells. SETD6-N is the truncated version of the protein that mimics the mutation found in our family; SETD6-C is a truncated SETD6 that
lacks the N-terminal part of the protein and the SET domain. The different versions of SETD6 were detected by western blot using an anti-FLAG antibody. GAPDH was
used as a loading control.
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On the other hand, although SETD6 c.791_792insA
(p.M264Ifs*3) is not a novel variant, it is quite rare in the general
population, with a minor allele frequency (MAF) of 0.001285 ac-
cording to ExAc and 0.00123 when the TCGA cohort is removed
(47). Moreover, it is not found in the 1000 Genomes Project nor ob-
served in homozygous state in neither of these databases.
Finally, this variant produces a shift in the reading frame of the
codons, and is therefore predicted to be Disease Causing by the
MutationTaster software (48) (score¼ 1), further supporting its
pathogenicity.
SETD6 c.791_792insA (p.M264Ifs*3) results in the loss of
the C-terminal half of the protein
As mentioned above, the identified SETD6 mutation (Fig. 1B)
results in a frameshift with the consequent introduction
of two new amino acids at positions 264 and 265
(ENST00000310682)—Ile264 and Gly265, instead of the original
Met and Ala—followed by a premature stop codon (Fig. 2A).
The resulting truncated SETD6 has an intact SET domain but
lacks the C-terminal half of the protein, which includes a
linker sequence and the whole Rubisco domain, presumably
responsible of mediating protein-protein interactions (49) (Fig.
2B). With the aim of checking whether mutant SETD6 is stable
and normally expressed, a truncated version of the protein
mimicking the frameshift mutation—hereon referred to as
SETD6-N—was cloned and overexpressed. SETD6-N was found
to be expressed to the same extent as wild-type SETD6 both in
HEK293T and HCT116 cells (Fig. 2C and D, respectively). It is
worth noting that an attempt to overexpress the C-terminal
half of SETD6 (containing everything which SETD6-N is miss-
ing) was unsuccessful. Our working hypothesis was that the
premature termination of the protein would impair SETD6’s
cellular function.
SETD6-N shows the same localization pattern as
wild-type SETD6
In order to test if the SETD6 mutation affects its subcellular lo-
calization, HEK293T and HCT116 cells were transfected with
GFP-tagged SETD6 (either SETD6 wt or SETD6-N). Fluorescence
microscopy of the transfected cells revealed that SETD6-N pre-
sented the same distribution within the cell as the wild type,
both of which were mainly concentrated to the nucleus (Fig. 3A
and B). We could detect, however, the presence of speckles in-
side the nucleus of the cells expressing mutant SETD6, which
suggested that the association with the chromatin might be al-
tered. To better understand the localization pattern, both pro-
teins were transfected into cells followed by a biochemical
fractionation of the cytosolic and chromatin fractions (50). This
experiment confirmed a similar subcellular localization be-
tween the mutant and the wild-type, with no significant differ-
ences in the cytosolic fraction (Fig. 3C and D). Some differences
between the wild-type and SETD6-N were only observed at the
chromatin level. To further establish the presence of mutant
SETD6 at chromatin, we used an additional method to extract
the chromatin (see the Materials and Methods section for more
details). This experiment confirmed comparable amounts of
SETD6 wt and SETD6-N at this fraction (Fig. 3E and F). This data
suggests that SETD6-N shows the same chromatin localization
pattern as the wild-type enzyme.
Recombinant SETD6-N binds its substrates to the same
extent as wild-type SETD6
We next performed an ELISA experiment to test whether the
studied mutation would affect the binding ability of SETD6 in a
cell-free in vitro system. To this end, we compared the direct
binding of the wild type and SETD6-N to two well-known
A B C
D E F
Figure 3. SETD6-N shows similar subcellular localization as wild-type SETD6. (A, B) HEK293T (A) and HCT116 (B) cells were transfected with GFP-tagged empty,
SETD6 wt or SETD6-N plasmids. The distribution of GFP within the cells was observed by fluorescence microscopy. (C, D) HEK293T (C) or HCT116 (D) cells were trans-
fected with FLAG-SETD6 (wt or N) and biochemically separated into cytoplasmic (Cyt) and chromatin (Chr) fractions. SETD6 was detected by western blot with an anti-
FLAG antibody. Histone H3 and a-tubulin were used as chromatin and cytoplasmic controls, respectively. (E, F) The chromatin fraction of HEK293T (E) or HCT116 (D)
cells transfected with FLAG-SETD6 (wt or N) was isolated and SETD6 was detected by western blot using the indicated antibodies. Histone H3 was used as a chromatin
control.
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substrates, RelA and PAK4 (40,42). Recombinant RelA and PAK4
were used to coat an ELISA plate, together with BSA, which was
used as a negative control. Recombinant SETD6 wt, SETD6-N
and SUMO were used as tested proteins, with the latter as an-
other negative control. As shown in Figure 4A–C, SETD6-N
bound at equal levels to both substrates as did wild-type SETD6,
which suggests that the mutation does not impair the interac-
tion between SETD6 and its substrates in vitro.
Recombinant SETD6-N fails to methylate its substrates
To compare the enzymatic activity of wild-type SETD6 and
SETD6-N, both proteins were subjected to a cell-free in vitro
methylation assay with RelA and PAK4 as substrates (Fig. 5A
and B, respectively). As expected, both substrates were specifi-
cally methylated by wild-type SETD6. However, no methylation
was observed when SETD6-N was present in the reaction in-
stead. It is of note that SETD6’s automethylation activity was
also lost in the truncated mutant. Consistent with these results,
we found that while the recombinant wild-type SETD6 methyl-
ated immunoprecipitated RelA and PAK4 from HEK293T cells,
SETD6-N failed to do so (Fig. 5C and D, respectively). In a recip-
rocal experiment, we observed that recombinant RelA and PAK4
were specifically methylated by wild-type SETD6 isolated from
human cells and not by SETD6-N (Fig. 5E and F, respectively).
These complementary assays further demonstrate that the
SETD6 truncating mutation identified in the FCCTX family abro-
gates the enzymatic activity of SETD6.
SETD6-N binds its substrates but loses its activity in
colon cancer cells
Since the SETD6 mutation was identified in hereditary colon
cancer patients, we next aimed to confirm our findings in the
colon cancer cell line HCT116. For this purpose, either wild-type
SETD6 or SETD6-N were overexpressed in the presence or ab-
sence of FLAG-RelA (Fig. 6A). As expected, SETD6 wt and SETD6-
N physically interacted with RelA at the chromatin to the same
extent. Consistent with our cell-free in vitro experiments, we
also observed that while SETD6 wt methylated RelA, SETD6-N
did not. The methylation of RelA at the chromatin was identi-
fied using a RelAK310me1 antibody that could specifically
recognize monomethylation of RelA at position K310 (40). The
same results were obtained when PAK4 was used as the sub-
strate (Fig. 6B). These findings support the dominant negative
nature of SETD6 c.791_792insA (p.M264Ifs*3) in a colon cancer
cellular model.
Both wild-type and mutant SETD6 are expressed in the
tumor and compete for their substrates
Last but not least, we aimed to check if SETD6’s mutant allele
was expressed, given that the variant was carried in heterozy-
gosis. To this end, a digital PCR was carried out using two
TaqMan probes that specifically recognized either the wild-type
or the mutant cDNA (with the insertion of the adenine). As ob-
served in Figure 7A and B, the tumor from member II: 2 showed
positive expression of both alleles. As expected, all non-carrier
controls only expressed the wild-type allele.
The fact that both alleles were expressed raised the question
of whether mutant and wild-type SETD6 would compete for
their substrates. In order to address this issue, a cell-free in vitro
methylation competition assay was performed in the presence
of recombinant SETD6 wt and different amounts of recombinant
SETD6-N, using RelA as the substrate. Figure 7C shows how
wild-type SETD6’s activity was inhibited in the presence of
SETD6-N in a concentration-dependent manner, with a signifi-
cant reduction in the amount of methylated substrate even
when the same amount of each form of the enzyme was pre-
sent (lanes 2 and 3, respectively). Finally, a competition assay in
HCT116 cells confirmed the cell-free in vitro results, showing
that the methylation of RelA at K310 in cells is reduced upon
SETD6-N overexpression in a dose-dependent manner (Fig. 7D).
Taken together, these results suggest that the expression of the
mutant allele in the carriers is expected to compete with the en-
zymatic activity of SETD6 wt, supporting a dominant negative
role of this mutation.
Discussion
Familial colorectal cancer type X (FCCTX) is a term used to de-
scribe a heterogeneous group of CRC families for whom the ge-
netic basis underlying their cancer predisposition remains
unknown. Genome-wide analyses of gene expression patterns
A B C
Figure 4. Recombinant SETD6-N shows similar binding to its substrates RelA and PAK4 as wild-type SETD6. (A) Interaction between recombinant SETD6 (wt or N) and
PAK4/RelA determined by an ELISA. The plate was coated with 2 lg of His-PAK4, MBP-RelA or BSA (negative control), and then covered with 0.5 lg of His-SETD6 wt, His-
SETD6-N or His-SUMO (negative control). Bound proteins were detected using a rabbit anti-SETD6 antibody. Data and error bars are from two technical replicates and
represent two independent biological experiments. (B, C) Coomassie staining for the coating (B) and tested (C) proteins used in the ELISA.












Figure 5. SETD6-N fails to methylate its substrates RelA and PAK4. (A, B) Cell-free in vitro methylation assays in the presence of 3 H-SAM, recombinant His-SETD6 (wt or
N) and either MBP-RelA (A) or His-PAK4 (B). The methylated proteins were detected by autoradiogram (top images), and the input used in the reactions is shown by
Coomassie staining (bottom). (C, D) HEK293T cells were transfected with FLAG-RelA (C), FLAG-PAK4 (D) or empty plasmid. Cell extracts were immunoprecipitated with
anti-FLAG M2 beads, followed by a radioactive cell-free in vitro methylation assay in the presence of 3 H-SAM and recombinant His-SETD6 (wt or N). The methylated
proteins were detected by autoradiogram (top images), and the input used in the reactions was shown by Coomassie staining (bottom). (E, F) HCT116 cells were trans-
fected with either FLAG-SETD6 wt, FLAG-SETD6-N or empty plasmid. Cell extracts were immunoprecipitated with anti-FLAG M2 beads, followed by a radioactive cell-
free in vitro methylation assay in the presence of 3 H-SAM and recombinant MBP-RelA (E) or His-PAK4 (F). The methylated proteins were detected by autoradiogram (top
images), and the input used in the reactions was shown by Coomassie staining (bottom).
A B
Figure 6. SETD6-N binds its substrates RelA and PAK4, while failing to methylate them, in the colon cancer cell line HCT116. (A, B) HCT116 cells were transfected with
either HA-SETD6 wt or HA-SETD6-N plasmids, in the absence or presence of FLAG-RelA (A) or FLAG-PAK4 (B). The chromatin fraction was then immunoprecipitated
with anti-FLAG M2 beads and analysed by western blot with the indicated antibodies.
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in FCCTX in comparison to Lynch syndrome tumors (15) have
shown differences in three major cancer-related pathways: cell
cycle progression, oxidative phosphorylation and G protein-
coupled receptor signaling, all of which have been previously
linked to CRC (51–53). The fact that different genes are ex-
pressed in the tumors of FCCTX and Lynch syndrome patients
may suggest that different molecular mechanisms mediate the
progression of these two pathologies. FCCTX presumably com-
prises different yet-to-be-discovered genetic syndromes involv-
ing high-penetrance mutations in novel cancer-predisposing
genes. However, it is thought that some FCCTX cases would re-
sult from a combination of low-penetrance mutations in differ-
ent genes, or even from aggregation of sporadic cases due to
shared lifestyle factors (5), what makes their study more diffi-
cult. The arrival of Next-Generation Sequencing (NGS) has been
an important milestone in the search for new predisposition
genes that explain the cancer heritability in these families.
Nevertheless, this task is still a challenge and it is believed that
the best strategy is to address each family individually, due to
their wide diversity.
Using whole-exome sequencing, a rare frameshift mutation
in the SETD6 gene was identified in a FCCTX family. This
mutation was found to cosegregate with the disease within the
family, since it was carried by three CRC-affected members (II:
1, II: 2 and II: 4) while absent in three healthy relatives (II: 3, III: 1
and III: 2). No LOH was observed in the tumor of member II: 2,
suggesting that in this family the SETD6 mutation does not fol-
low Knudson‘s two-hit mechanism for tumor suppressor genes,
consistent with a dominant negative nature. Nonetheless, the
LOH does not predict the pathogenicity of a mutation, since it
has been reported to have a dual role in HNPCC families, with
no preferential loss of the wild-type or the mutant allele. As a
matter of fact, different carriers of well-known pathogenic MMR
mutations have been reported to show the three different LOH
statuses (no LOH, LOH of the mutant and LOH of the wild-type),
even within the same family (54).
Regarding the consequences of the studied SETD6 mutation,
this variant results in the introduction of two amino acids at po-
sitions 264 and 265 followed by a premature stop codon. The
truncated protein (SETD6-N) lacks its C-terminal half but retains
an intact SET domain, which is responsible for its catalytic ac-
tivity. Here, we show that mutant SETD6 exhibits dominant
negative properties in cell-free in vitro systems and in a colon




Figure 7. Both wild-type and mutant SETD6 are expressed in the tumor and compete for their substrates. (A) Allele-specific expression obtained by digital PCR pre-
sented as Target/Total, where “Target” is the mutant SETD6 allele (detected with the FAM dye). Data from the tumor of II:2 was collected from three independent
experiments, and the error bars correspond to the confidence intervals. The Control represents tumor cDNA from four different sporadic CRC patients used as non-car-
rier controls. (B) Digital PCR visualization of the cDNA from the tumor of member II:2 (top) and a non-carrier control (bottom). The FAM dye detects the mutant allele,
while the VIC dye detects the wild-type allele. (C) Radioactive cell-free in vitro methylation assay in the presence of recombinant wild-type SETD6 and different
amounts (+ and ++) of recombinant SETD6-N. The methylated proteins were detected by autoradiogram (top), and the input used in the reactions is shown by
Coomassie staining (bottom). (D) HCT116 cells were transfected with HA-SETD6 wt, FLAG-RelA and with or without different concentrations (þ and þþ) of HA-SETD6-
N. The chromatin fraction was then immunoprecipitated with anti-FLAG M2 beads and analyzed by western blot with the indicated antibodies.
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similar localization, expression and binding to its known part-
ners as the wild-type, the mutant protein loses its enzymatic
activity. Indeed, unlike wild-type SETD6, SETD6-N lacks both its
automethylation activity and the ability to methylate two previ-
ously identified substrates, PAK4 and RelA (40,42). In addition,
the two alleles (wild type and mutant) were found to be ex-
pressed in the tumor of one of the carriers, and the two forms of
SETD6 were shown to compete for their substrates both in cell-
free systems and in a colon cancer cellular model, pointing to a
dominant negative role. As a result, this mutation may have
several downstream effects on the different pathways in which
SETD6 is involved. For example, SETD6-dependent methylation
of the NF-jB subunit RelA has been shown to be critical for basal
inhibition of NF-jB signaling in the absence of stimulation (40).
The NF-jB family of transcription factors has an essential role
in inflammation and innate immunity, but it has also been in-
creasingly recognized as a crucial player in many steps of can-
cer initiation and progression (55). In fact, activation of the NF-
jB pathway has been positively associated with multiple types
of cancer, including CRC (56). In addition, we had previously
demonstrated that methylation of PAK4 by SETD6 promotes the
activation of the Wnt/b-catenin pathway (42). On the other
hand, deregulation of the Wnt signaling pathway has been
shown to contribute to CRC development, including in HNPCC
(57–60). Thus, the loss of SETD6’s function, together with the ab-
errant regulation of NF-jB and/or Wnt signaling, could contrib-
ute to the initiation or progression of CRC in the studied FCCTX
family. However, since SETD6 has several other substrates and
is involved in numerous other signaling pathways (41,43,45,46),
future studies are needed in order to define the downstream
consequences of this SETD6 truncating mutation that we have
identified.
Given all the results presented above, we propose that the
presence of SETD6’s mutant allele would presumably increase
the cumulative risk of developing colorectal cancer throughout
the life of the carriers, as compared with the general population.
More research should be done in order to determine the pene-
trance of this mutation (that is to say the percentage of individ-
uals who present this variant that will develop the disease,
which is not complete even in well-known pathogenic MMR
variants), whether it is a high, moderate or low-risk allele, and if
there is also an association with other CRC-related cancers.
Interestingly, the same SETD6 frameshift mutation had already
been proposed to be associated with ovarian cancer in an exten-
sive study by Kanchi and colleagues (61). Nonetheless, the
search for new genes by exome sequencing in FCCTX families
has demonstrated that more than one gene can be implicated
in their increased risk of developing cancer. Actually, even
when there is a high-risk gene involved, there might be also
low-penetrance alleles that cooperate in the process as risk
modifiers. Apart from these polygenic approaches, there are
many other factors that might take part in modulating the can-
cer risk, including lifestyle and other environmental factors. For
all these reasons, our results are not enough to claim that
SETD6 alone is responsible for the increased CRC-risk in this
FCCTX family. Hence, it is still difficult to know the effect that
this mutation might have in the other carriers found in the pub-
lic databases, as much as it is hard to predict if they are going to
develop cancer at some point in their life or even if they have al-
ready developed it.
Noteworthy, the whole-exome sequencing followed by rigor-
ous filtering identified additional candidate genes beside SETD6
(Supplementary Material, Table S2). For instance, CCDC60
showed a stop gain variant that results in the loss of 30 amino
acids, 20 of which belong to a domain of unknown function,
while the remaining 10 belong to a low complexity region.
Another candidate was L3MBTL1, located on the long arm of
chromosome 20 within a region that has been previously shown
to be deleted in several malignancies (62). This gene presented a
splicing variant that does not imply the gain or loss of a splicing
acceptor/donor, but that is predicted to create a new exonic
splicing silencer site instead. Finally, missense mutations were
found in CCDC62, previously linked to prostate cancer (63), and
in the polyadenylation regulating factor WDR33 (64). Both vari-
ants affect low complexity regions of the corresponding pro-
teins, and although they are predicted to be damaging in silico,
they do not alter any known protein domains. While the current
paper focuses on SETD6, we cannot exclude the possibility that
the additional candidate variants identified may contribute in-
dependently or together to the pathology of FCCTX.
Together, our findings suggest that a truncating dominant
negative mutation in SETD6 could potentially explain the can-
cer predisposition of this FCCTX family. These results certainly
point to a pathogenic role of SETD6 c.791_792insA (p.M264Ifs*3),
though not enough to prove that SETD6 alone is responsible for
their increased cancer risk. Although no other SETD6 variants
were found in the remaining 12 families that were studied, nor
in 109 familial CRC cases provided by Dr. Castellvi-Bel (Hospital
Clinic, IDIBAPS, Barcelona, Spain), the screening of this gene in
a larger group of patients could provide more insights into its
role in other FCCTX families.
Materials and Methods
Study population
The studied family (cc598) was selected among a group of
FCCTX families collected in the Genetic Counseling Unit at the
Hospital Clı́nico San Carlos of Madrid. All FCCTX families ful-
filled the Amsterdam I or II criteria for HNPCC (7) (at least three
relatives with CRC or other related cancers, one being a first
degree relative of the other two, with at least two successive
generations involved, the earliest age of onset being 50 years
old or lower and familial adenomatous polyposis excluded). In
addition, all the CRC tumors from these families were MSS and
presented normal expression of the MMR proteins. The study
was approved by the Institutional Review Boards of the
Hospital Clı́nico San Carlos, and an informed consent was ob-
tained from each participant. Personal and family histories
were obtained from the proband and participating relatives,
and cancer diagnoses were confirmed by medical and pathol-
ogy records.
Family cc598
Family cc598 (Fig. 1A), selected for the whole-exome study, is an
Amsterdam I family in which the father (I: 1) was diagnosed
with CRC at the age of 80. He had two daughters and two sons,
three of whom were diagnosed with CRC at ages 64 (II: 1), 56 (II:
2) and 34 (II: 4). Only one daughter was healthy (II: 3). The stage
and location of the CRCs developed by II: 1, II: 2 and II: 4 were
pT3N0M1 (splenic flexure, left colon), pT2N0M0 (right colon) and
pT3N1M0 (rectum), respectively. The tumors from members II: 1
and II: 4 were MSS and showed normal expression of the MMR
proteins (MLH1, MSH2, MSH6 and PMS2) (Supplementary
Material, Table S1). The whole-exome sequencing was per-
formed in germline DNA from members II: 1, II: 2 and II: 3.
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DNA and RNA extraction
Germline DNA and RNA were extracted from peripheral blood
using the MagNA Pure Compact extractor system (Roche
Diagnostics), according to the manufacturer’s protocol. The
PAXgene Blood RNA Kit (PreAnalytiX) was used to extract germ-
line RNA conforming to its manual when the patient could not
come to our hospital. Tumor DNA and RNA were extracted from
7 mm-thick haematoxylin/eosin-stained sections of the paraffin-
embedded tumor tissues with a tumor content of more than
80% as determined by two experienced pathologists. Tumor
DNA was extracted using the QIAamp DNA FFPE Tissue Kit from
Qiagen, while tumor RNA was isolated employing the RNeasy
FFPE Kit (Qiagen), according to their corresponding protocols. A
NanoDropVR (ND1000) spectrophotometer was used to assess the
DNA quantity and quality.
Whole-exome sequencing
The whole-exome sequencing was outsourced to Sistemas
GenómicosVR . Library preparation for the capture of selected
DNA regions was performed according to Agilent‘s SureSelect
protocol for Illumina paired-end sequencing (SureSelectXT
Human All Exon V3, 51 Mb, Agilent Technologies). The final li-
brary size and concentration were determined on an Agilent
2100 Bioanalyzer and a Qubit Fluorometer (Thermo Fisher
Scientific), respectively. Finally, the library was sequenced on
an Illumina HiSeq 2000 platform with paired-end reads of
101 bp, following the manufacturer‘s protocol. Images produced
by the HiSeq 2000 were processed using the manufacturer‘s
software to generate FASTQ sequence files. Reads were aligned
against the human reference genome version GRCh37/hg19 us-
ing the BWA software, creating the BAM files. Low quality reads,
PCR duplicates and other sequences that could introduce major
biases were removed using Picard-tools (http://picard.source
forge.net/) and SAMtools (65). Variant calling was performed us-
ing a combination of two different algorithms [VarScan (66) and
GATK (67)] and the identified variants were annotated using the
HGMD (68) and Ensembl (69) databases.
Filtering and prioritization of the variants
The variants identified by whole-exome sequencing where sub-
sequently filtered as follows: 1. Variants shared by the two af-
fected members but not by the healthy relative were selected. 2.
Homozygous variants were discarded, as well as variants pre-
sent in allosomes. 3. Only coding non-synonymous (missense,
stop gain, stop loss, in-frame, frameshift) and splicing variants
were selected. 4. Variants with a minor allele frequency (MAF)
in the general population greater than 0.01 were eliminated. 5.
Missense and in-frame variants not predicted to be damaging
by in silico programs [SIFT (70), Polyphen (71), MutationTaster
(48)] were discarded, as well as splicing variants not directly af-
fecting the donor/acceptor sites nor predicted to alter the splic-
ing by the Human Splicing Finder (HSF) (72). Finally, the filtered
variants were prioritized according to the genes and pathways
involved.
Variant validation, segregation and loss of
heterozygosity (LOH) studies
All the candidate variants were validated by PCR followed by
Sanger sequencing of the corresponding region of each gene,
using specific primers that were designed with Primer3 (73). The
segregation and LOH studies for the SETD6 variant were also as-
sessed by PCR and subsequent Sanger sequencing of the se-
lected area of the SETD6 gene (exon 7, ENST00000310682). The
segregation study was carried out in germline DNA from the
available members of the family (III: 1 and III: 2). However, al-
though no germline DNA was available from the deceased
member II: 4, we were able to study the segregation in this
member extracting DNA from the paraffin-embedded tumor.
For the LOH analysis, tumor DNA was extracted from the
paraffin-embedded tumor available, and the electropherograms
of the germline and tumor sequences were compared, allowing
the discrimination of the wild-type and the mutant alleles. LOH
was considered when the intensity of any allele was reduced by
50% relative to the other allele. The SETD6 primers used for
the PCRs were CCACTCAGCCCATTCCTAAA (forward) and
TGATACACTCACCCTGTAATGCT (reverse).
Plasmids and cloning
The wild-type SETD6 gene, as well as mutant SETD6 (with the
same variant identified in family cc598), was amplified by high-
fidelity PCR and cloned into pcDNA3.1 and pET-Duet plasmids
for overexpression and protein purification, respectively. The
pcDNA3.1 plasmids in which the two forms of the gene were
subcloned include pcDNA3.1-FLAG, pcDNA3.1-HA and
pcDNA3.1-GFP, for the different experiments. In the same way,
RelA and PAK4 were also cloned into pcDNA3.1-FLAG for the
overexpression experiments (42) and pMAL-c2x or pET-Duet
plasmids (respectively) for the expression and purification of
the recombinant proteins.
Cell lines and transfection
Two different cell lines were used in this study: human embry-
onic kidney cells (HEK293T) and human colon carcinoma cells
(HCT116). Both were maintained in Dulbecco‘s modified Eagle‘s
medium (Sigma-Aldrich, D5671) with 10% fetal bovine serum
(Gibco), 2 mg/ml L-glutamine (Sigma-Aldrich, G7513), 1%
penicillin-streptomycin (Sigma, P0781) and non-essential amino
acids (Sigma-Aldrich, M7145), and they were cultured at 37 C in
a humidified incubator with 5% CO2. For transient transfection,
Mirus transfection reagents (TransITVR -LT1 for HEK293T cells
and TransITVR -X2 for HCT116 cells) were used according to the
manufacturer‘s instructions, together with Opti-MEM serum-
free medium (Gibco).
Western blot analysis
For western blot analyses, cells were homogenized and lysed in
RIPA buffer [50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM DTT, and 1:
100 protease inhibitor mixture (Sigma-Aldrich)], except for the
biochemical fractionation and chromatin immunoprecipitation
experiments, in which the cells were lysed as described below.
Samples were heated at 95 C for 5 min in Laemmli sample buf-
fer, run on a 8-12% SDS-PAGE electrophoresis gel, and then
transferred to a polyvinylidene difluoride (PVDF) membrane.
Membranes were blocked with either 10% skim milk in PBST or
5% BSA in TBST for 1 h on a shaking platform, and subsequently
incubated with primary antibody for another hour with agita-
tion. After three washes with the corresponding buffer (PBST or
TBST), a 30-min incubation with HRP-conjugated secondary an-
tibody and three additional washes, a 2-min reaction with a
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chemiluminiscent substrate (EZ-ECL, Biological industries, 20-
500-120) allowed the visualization of the proteins.
The mouse monoclonal antibodies used were: anti-FLAG M2
(Sigma-Aldrich, F1804), anti-HA (Millipore, 05–904), anti-GAPDH
(Abcam, ab8245), anti-SETD6 (Genetex, GTX629891), and anti-
histone H3 (Abcam, ab10799). The rabbit polyclonal antibodies
used were: an HRP-conjugated pan methyl lysine antibody
(ImmuneChem, ICP0502) and a specific antibody against mono-
methylated RelA-Lys310 developed by Levy et al. (40). HRP-
conjugated secondary antibodies (goat anti-rabbit and goat
anti-mouse) were purchased from Jackson ImmunoResearch
(111-035-144 and 115-035-062, respectively). Antibodies were di-
luted and prepared in PBST with 10% skim milk or in TBST with
5% BSA, according to the manufacturer‘s recommendations.
Biochemical fractionation
Biochemical fractionation was performed as previously de-
scribed by Mendez et al. (50), with the addition of a final resus-
pension of the chromatin pellet for 30 min on ice in RIPA buffer
with 1 mM MgCl2 and benzonase nuclease enzyme (Sigma-
Aldrich). The chromatin fraction was obtained by the collection
of the supernatant after low-speed centrifugation (5 min, 1700 g,
4 C).
Recombinant protein expression and purification
The Escherichia coli BL21-derivative Rosetta host strain was
transformed with pET-Duet plasmids containing the gene of
interest (SETD6 wt, SETD6-N, PAK4 or RelA) and grown over-
night in 3 ml LB mediumþ100 lg/ml ampicillin (37 C, 220 rpm).
The culture was then expanded to 100 ml LB medium and in-
cubated at 37 C until the absorbance (OD) reached values of
0.6–0.8, when it was induced with 1: 10000 IPTG and left over-
night at 18 C and 220 rpm. After IPTG induction, the bacteria
were harvested by centrifugation (10 min, 12000 rpm, 4 C), re-
suspended in cold lysis buffer (10 mM imidazole, 1% PMSF,
protease inhibitor cocktail, 0.1% triton and PBS) and then lysed
by sonication on ice (25% amplitude, 1 min 30 s, 10 s on/5 s off).
Finally, the lysate was centrifuged (20 min, 4 C, 18000 rpm)
and filtered, and the His-tagged proteins were purified using
an ÄKTATM column.
ELISA
A high-binding 96-well polystyrene microplate (Greiner Bio-One
MICROLONVR ) was coated with 2 mg of the recombinant proteins
of interest (His-PAK4, MBP-RelA or BSA) diluted in PBS. The plate
was blocked with 3% BSA in PBST and subsequently covered
with 0.5 mg of the recombinant tested proteins (His-SETD6 wt,
His-SETD6-N or His-SUMO as a control) diluted in 1% BSA in
PBST. The rabbit polyclonal anti-SETD6 primary antibody (40)
was then added, followed by incubation with an HRP-
conjugated secondary antibody (goat anti-rabbit, 1: 2000;
Jackson ImmunoResearch, 111-035-144). All the incubation
steps were performed at room temperature with vigorous agita-
tion for 1 h, and followed by three washes with PBST. After the
final washes, 100 ll of TMB reagent were added to each well,
succeeded after a few minutes by the same amount of 1 N
H2SO4, in order to stop the reaction. The absorbance at 450 nm
was then detected using an InfiniteVR M200 plate reader (Tecan).
All samples were analysed in duplicates.
Cell-free in vitro methylation assay
Cell-free in vitro methylation reactions with recombinant pro-
teins took place in a final volume of 25 ll, containing 4 lg of sub-
strate (His-PAK4 or MBP-RelA), 4 lg (or increasing amounts for
the competition assay) of His-SETD6 (either wt or N), 2 mCi of
3 H-labeled S-adenosyl-methionine (SAM) (AdoMet, Perkin-
Elmer) and PKMT buffer (20 mM Tris-HCl, pH 8, 10% glycerol,
20 mM KCl, 5 mM MgCl2). The reaction tubes were incubated
overnight at 30 C and then resolved by SDS-PAGE electrophore-
sis and subsequent autoradiogram. For the immunoprecipita-
tion followed by cell-free in vitro methylation, human cells were
transfected with empty, FLAG-SETD6 wt, FLAG-SETD6-N, FLAG-
RelA or FLAG-PAK4 pcDNA3.1 plasmids, and 24 h post-
transfection they were lysed with RIPA buffer and pulled down
overnight with anti-FLAG M2 Affinity gel beads (Sigma-Aldrich,
A2220) on a rotor at 4 C. After two washes in RIPA buffer and
another two in PKMT buffer, samples were subjected to an on-
beads cell-free in vitro methylation assay as described above.
Protein–protein chromatin immunoprecipitation
Protein-protein chromatin immunoprecipitation was modified
from a published protocol (74). After cross-linking, cells were
harvested and washed twice with PBS and then lysed in 1 ml of
lysis buffer (20 mM Tris-HCl, pH 8, 85 mM KCl, 0.5% Nonidet
P-40, and 1: 100 protease inhibitor mixture) for 10 min on ice.
Nuclear pellets were resuspended in 200 ll of nuclei lysis buffer
(50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS, 1: 100 protease in-
hibitor mixture) for 10 min on ice, and sonicated (Bioruptor,
Diagenode) with high power settings for three cycles of 6 min
each (30 s on/off). Samples were then centrifuged (20 min,
13000 rpm, 4 C), and the soluble chromatin fraction was col-
lected. The FLAG-labeled substrates present in the soluble chro-
matin were then immunoprecipitated overnight on a rotor at
4 C, using 20 ll per tube of anti-FLAG M2 Affinity gel beads
(Sigma-Aldrich, A2220). The beads were then washed according
to the published protocol, heated for 30 min in Laemmli sample
buffer at 95 C, and resolved on 10-12% SDS-PAGE gels followed
by western blot analyses.
Reverse transcription polymerase chain reaction and
digital PCR
Reverse transcription polymerase chain reaction (RT-PCR) was
performed to convert RNA into complementary DNA (cDNA) us-
ing the PrimeScript RT Reagent Kit (Perfect Real Time) (Takara,
Clontech), following the kit’s instructions. For the expression
assays, a TaqMan digital PCR (dPCR) was carried out taking ad-
vantage of the QuantStudioTM 3 D Digital PCR System (Thermo
Fisher Scientific), according to the manufacturer’s recommen-
dations. The primers and TaqMan probes used in the dPCR were
designed with the Custom TaqManVR Assay Design Tool
(Thermo Fisher Scientific) and produced by the same company.
The FAM probe specifically identified the mutant transcript,
while the VIC probe only recognized the wild type. The dPCR
was used to analyse the cDNA from the paraffin-embedded tu-
mor of member II: 2. Tumor cDNA from four sporadic CRC pa-
tients were used as non-carrier controls.
Supplementary Material
Supplementary Material is available at HMG online.
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